0QLR.IL - Novartis AG

FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer

Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.

Here's Why Novartis (NVS) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for Novartis (NVS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

• 
  U.S. Steel (X) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

  Zacks
• 
  Here's Why Britvic PLC Sponsored ADR (BTVCY) Could be Great Choice for a Bottom Fisher

  Zacks

Novartis drug cuts recurrence risk by 25% in early-stage breast cancer

Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly. The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. The results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.

Bayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies

Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.

Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?

Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.

AstraZeneca (AZN) Discontinues Brazikumab Development

AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis

Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.

Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review

Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.

Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal

Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.

5 Large Drug Stocks to Watch From a Thriving Industry

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.

Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition

Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

Here is how Adma Biologics (ADMA) and Novartis (NVS) have performed compared to their sector so far this year.

• 
  Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?

  Zacks
• 
  Is Clorox (CLX) Stock Outpacing Its Consumer Staples Peers This Year?

  Zacks

Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion

Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.

Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation

Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.

Time to Buy Stock in These Pharmaceutical Giants for EPS Growth

The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.

Alimera (ALIM) Completes Enrollment in Eye Disease Study

Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.

Novo Nordisk (NVO) Collaborates for Gene-Editing Therapies

Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.

AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab

The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.

Novartis (NVS) Up 10.8% YTD on Strong Q1, Pipeline Progress

Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.

Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease

AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.

Is Novartis AG's (VTX:NOVN) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Most readers would already be aware that Novartis' (VTX:NOVN) stock increased significantly by 15% over the past three...

Roche's (RHHBY) MS Drug Meets Goals in the Phase II Study

Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.

Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag

Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.

Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth

Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.